← Back to Search

PET Imaging for Neuropsychiatric Disorders

Phase 1

Recruiting

Led By Alan Prossin, MBBS

Research Sponsored by The University of Texas Health Science Center, Houston

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Must be between 18-80 years old

Be older than 18 years old

Must not have

Females must not be pregnant or nursing

Must not be PBR-28 low affinity binder (or using the [11C]ER176 study radiotracer)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within 1-2 hours before petobtained during pet scanning (between 1:30 pm and 3 pm) at study baseline within a few days of study enrollment

Awards & highlights

No Placebo-Only Group

Summary

This trial will explore whether there is more inflammation in the brain of people with clinical evidence of neuropsychiatric syndromes.

Who is the study for?

This trial is for adults aged 18-45 who are right-handed and can sit still for long periods. It's open to healthy individuals or those with neuropsychiatric conditions like mood disorders, chronic pain, dementia, brain injuries, or substance abuse. Participants must not be pregnant, nursing, smokers, claustrophobic, drug users at the time of scanning (confirmed by a negative urine test), or have metal objects that could interfere with MRI.

What is being tested?

The study aims to detect brain inflammation in people with neuropsychiatric syndromes using PET scans with radiotracers [11C]PBR-28 or [11C]ER176. Researchers want to see if there's more inflammation in patients showing stronger symptoms of these conditions.

What are the potential side effects?

Potential side effects may include discomfort from sitting still during the PET scan and reactions related to the injection site of the radiotracer such as redness or swelling. There might also be rare allergic reactions to the tracer.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 80 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am not pregnant or breastfeeding.

Select...

I am not a low affinity binder for PBR-28.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ within 1-2 hours before petobtained during pet scanning (between 1:30 pm and 3 pm) at study baseline within a few days of study enrollment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~within 1-2 hours before petobtained during pet scanning (between 1:30 pm and 3 pm) at study baseline within a few days of study enrollment

This trial's timeline: 3 weeks for screening, Varies for treatment, and within 1-2 hours before petobtained during pet scanning (between 1:30 pm and 3 pm) at study baseline within a few days of study enrollment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Mental Depression

Affect as measured by the Positive and Negative Affect Schedule (PANAS)

Mental Status as measured by the Montreal Cognitive Assessment (MoCA)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: PET with radiotracer [11C]PBR-28 or [11C]ER176 and affective challengeExperimental Treatment2 Interventions

PET with radiotracer \[11C\]PBR-28 or \[11C\]ER176 will be performed. \[11C\]PBR-28 or \[11C\]ER176 will be injected into subjects' veins during PET scanning. Affective challenge (e.g. induction of mood, affective pain) will be presented to the patient during the PET scanning period.

Group II: PET with radiotracer [11C]PBR-28 or [11C]ER176Experimental Treatment1 Intervention

PET with radiotracer \[11C\]PBR-28 or \[11C\]ER176 will be performed. \[11C\]PBR-28 or \[11C\]ER176 will be injected into subjects' veins during PET scanning.

0 / 3Eligibility criteria met